Definitive Healthcare Corp. (DH) - 10-Q Summary for Q2 2025
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Definitive Healthcare Corp. operates a SaaS platform providing healthcare commercial intelligence to approximately 2,400 customers across Life Sciences, Provider, and Diversified markets. The company is an Accelerated Filer and reports on a consolidated basis with noncontrolling interests representing approximately 26.8% of ownership.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $60.8 million | $119.9 million | $127.2 million |
| Gross Profit | $46.6 million (77% margin) | $90.4 million (75% margin) | $100.8 million (79% margin) |
| Net Loss (GAAP) | $(9.3) million | $(164.4) million | $(318.9) million |
| Net Loss Attributable to DH | $(7.6) million | $(114.8) million | $(223.2) million |
| Adjusted EBITDA | $18.7 million (31% margin) | $33.4 million (28% margin) | $40.9 million (32% margin) |
| Cash & Equivalents | $81.0 million | $81.0 million | $120.9 million (End of Period) |
| Short-Term Investments | $103.2 million | $103.2 million | $184.8 million (End of Period) |
| Term Loan Principal | $170.6 million | $170.6 million | $244.1 million (End of Period) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 5% year-over-year in Q2 and 6% year-over-year for the six months ended June 30, 2025. This was driven by a decrease in subscription revenue from existing customers, partially offset by growth from new customers and professional services.
- Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $176.5 million in Q1 2025 due to a decline in market capitalization. This contrasts with a $363.6 million charge in the same period in 2024. No impairment was recorded in Q2 2025.
- Debt Restructuring: In January 2025, the company amended its credit agreement, refinancing $175.0 million in term loans and $50.0 million in revolving credit. The company repaid $73.4 million of principal during the first six months of 2025.
- Operating Expenses: Operating expenses decreased significantly year-over-year, primarily due to the absence of the massive goodwill impairment charge seen in 2024 and cost reductions from the 2024 Restructuring Plan.
Guidance, Outlook, and Risks
- Revenue Outlook: Management expects revenue to decline in 2025 compared to 2024 due to lower renewal rates, sales execution challenges, and macroeconomic headwinds.
- Customer Trends: Total customer count decreased to approximately 2,400 from 2,600 in the prior year. Enterprise customers (>$100k ARR) decreased to 510 from 537. Churn is notably higher among smaller customers and in the Life Sciences sector.
- Key Risks:
- Macroeconomic Conditions: Lengthening deal cycles, deferred purchasing decisions, and heightened churn.
- Data Costs: Disruptions in healthcare claims data sources may negatively impact data acquisition costs.
- Goodwill Impairment Risk: The reporting unit remains at risk for future impairment if market capitalization continues to decline.
- Tax Receivable Agreement (TRA): Significant liability ($31.2 million) exists for payments to pre-IPO holders based on future tax benefits realized.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the revenue decline and the specific churn rates within the Life Sciences segment.
- Goodwill Valuation: Assess the sensitivity of the remaining goodwill ($216.8 million) to further stock price declines.
- Liquidity Position: Confirm the ability to service debt obligations ($170.6 million principal) given the projected revenue decline and ongoing cash burn.
- TRA Liability: Review the assumptions used to calculate the Tax Receivable Agreement liability and the potential cash outflow impact.
- Non-GAAP Reconciliations: Scrutinize the Adjusted EBITDA reconciliation, specifically the treatment of the TRA remeasurement and stock-based compensation.